28.10.2016 12:00:48

Press Release: MorphoSys to Host Q3 2016 Conference Call on November 7, 2016

MorphoSys AG / MorphoSys to Host Q3 2016 Conference Call on November 7, 2016 . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first nine months' 2016 results on November 7, 2016 at 7:00 am CET.

At 2:00 pm CET (1:00 pm GMT, 8:00 am EST), the Management Board of MorphoSys AG will host a public conference call and webcast to present MorphoSys's financial results for the first nine month of 2016 and provide further details on the Company's latest developments.

Dial-in numbers (listen only):

Germany: +49 89 2444 32975

United Kingdom: +44 20 3003 2666

USA: +1 202 204 1514

We request that you please dial in up to 10 minutes before the call to ensure a prompt start and a secure line.

The presentation slides and webcast link will be available at the Company's website at www.morphosys.com/conference-calls

A slide-synchronized audio replay of the conference will also be available at the corporate website following the live event.

About MorphoSys

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline http://www.morphosys.com/pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies, The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties, Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated, MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned

For more information, please contact:

MorphoSys AG

Dr. Claudia Gutjahr-Löser

Head of Corporate Communications & IR

Alexandra Goller

Senior Manager Corporate Communications & IR

Jochen Orlowski

Associate Director Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404

investors@morphosys.com

Q3 2016 Conference Call Alert: http://hugin.info/130295/R/2052333/768086.pdf

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Globenewswire

--- End of Message ---

MorphoSys AG

Lena-Christ-Str. 48 Martinsried / Munich Germany

WKN: 663200;ISIN: DE0006632003;Index:TECH All Share,CDAX,Prime All Share, TecDAX,HDAX,MIDCAP;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Berlin,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;

http://www.morphosys.com (END) Dow Jones Newswires

   October 28, 2016 05:30 ET (09:30 GMT)- - 05 30 AM EDT 10-28-16

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu MorphoSysmehr Analysen

06.05.24 MorphoSys Neutral UBS AG
30.04.24 MorphoSys Neutral UBS AG
16.02.24 MorphoSys Neutral UBS AG
07.02.24 MorphoSys Neutral UBS AG
07.02.24 MorphoSys Buy UBS AG
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Indizes in diesem Artikel

NASDAQ Comp. 20 026,77 0,41%